Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Timmerman

Showing results (221-230 of 229) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 229 results.
The Journal of Allergy and Clinical Immunology|October 12, 2016
Gram-positive anaerobe cocci are underrepresented in the microbiome of filaggrin-deficient human skinPatrick L J M Zeeuwen, Thomas H A Ederveen, Danique A van der Krieken, et al.
Reproductive Biomedicine Online|October 20, 2020
The long-term costs and effects of tubal flushing with oil-based versus water-based contrast during hysterosalpingographyNienke van Welie, Clarabelle T Pham, Joukje van Rijswijk, et al.
Annals of Surgery|October 6, 2009
Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitisMarc G Besselink, Hjalmar C van Santvoort, Willem Renooij, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 29, 2008
[Probiotic prophylaxis in patients with predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial]M G H Besselink, H C van Santvoort, E Buskens, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
The New England Journal of Medicine|May 19, 2017
Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile WomenKim Dreyer, Joukje van Rijswijk, Velja Mijatovic, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Pageof 23

Showing results (221-230 of 229) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 229 results.
The Journal of Allergy and Clinical Immunology|October 12, 2016
Gram-positive anaerobe cocci are underrepresented in the microbiome of filaggrin-deficient human skinPatrick L J M Zeeuwen, Thomas H A Ederveen, Danique A van der Krieken, et al.
Reproductive Biomedicine Online|October 20, 2020
The long-term costs and effects of tubal flushing with oil-based versus water-based contrast during hysterosalpingographyNienke van Welie, Clarabelle T Pham, Joukje van Rijswijk, et al.
Annals of Surgery|October 6, 2009
Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitisMarc G Besselink, Hjalmar C van Santvoort, Willem Renooij, et al.
Blood|February 23, 2023
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphomaSattva S Neelapu, Caron A Jacobson, Armin Ghobadi, et al.
Nederlands Tijdschrift Voor Geneeskunde|April 29, 2008
[Probiotic prophylaxis in patients with predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial]M G H Besselink, H C van Santvoort, E Buskens, et al.
The Lancet. Oncology|December 7, 2018
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trialFrederick L Locke, Armin Ghobadi, Caron A Jacobson, et al.
The New England Journal of Medicine|December 12, 2017
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaSattva S Neelapu, Frederick L Locke, Nancy L Bartlett, et al.
The New England Journal of Medicine|May 19, 2017
Oil-Based or Water-Based Contrast for Hysterosalpingography in Infertile WomenKim Dreyer, Joukje van Rijswijk, Velja Mijatovic, et al.
Journal for Immunotherapy of Cancer|December 27, 2016
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemiaMichael Boyiadzis, Michael R Bishop, Rafat Abonour, et al.
Pageof 23